Intranasal VLP-RBD vaccine adjuvanted with BECC470 confers immunity against Delta SARS-CoV-2 challenge in K18-hACE2-mice
F. H. Damron, K. S. Lee, N. A. Rader, O. A. Miller-Stump, M. Cooper, T. Y. Wong, M. S. Amin, M. Barbier, J. R. Bevere, R. K. Ernst
This study shows an intranasal VLP-RBD vaccine with BECC470 adjuvant provides protection against Delta SARS-CoV-2 in mice, with mucosal immunity and reduced lung inflammation.
bioRxiv · Apr 25, 2023Immunology